Who are OPC-12759's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Quetiapine or Risperidone + Aripiprazole, risperidone (Risperdal), Haloperidol + lorazepam, Abilify (aripiprazole), Cabergoline (Dopamine Agonist), sodium valproate with Clozapine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/opc-12759.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

OPC-12759 — Competitive Intelligence Brief

OPC-12759 (OPC-12759) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine D2 receptor antagonist. Area: Psychiatry.

phase 3 Dopamine D2 receptor antagonist D2 receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

OPC-12759 (OPC-12759) — Otsuka Pharmaceutical Co., Ltd.. OPC-12759 is a selective dopamine D2 receptor antagonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
OPC-12759 TARGET	OPC-12759	Otsuka Pharmaceutical Co., Ltd.	phase 3	Dopamine D2 receptor antagonist	D2 receptor
Quetiapine or Risperidone + Aripiprazole	Quetiapine or Risperidone + Aripiprazole	Otsuka Pharmaceutical Development & Commercialization, Inc.	marketed	Atypical antipsychotic	Dopamine D2 receptor, serotonin 5-HT2A receptor
risperidone (Risperdal)	risperidone (Risperdal)	University of South Florida	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Haloperidol + lorazepam	Haloperidol + lorazepam	University of Arkansas	marketed	Antipsychotic + benzodiazepine combination	Dopamine D2 receptor (haloperidol); GABA-A receptor (lorazepam)
Abilify (aripiprazole)	Abilify (aripiprazole)	Genovate Biotechnology Co., Ltd.,	marketed	Atypical antipsychotic	Dopamine D2 receptor (partial agonist), Serotonin 5-HT1A receptor (partial agonist)
Cabergoline (Dopamine Agonist)	Cabergoline (Dopamine Agonist)	University Hospital, Basel, Switzerland	marketed	Dopamine agonist	Dopamine D2 receptor
sodium valproate with Clozapine	sodium valproate with Clozapine	Shanghai Mental Health Center	marketed	Antipsychotic + mood stabilizer combination	Dopamine D2 receptor, serotonin 5-HT2A receptor, GABA pathways, histone deacetylase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine D2 receptor antagonist class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Idorsia Pharmaceuticals Ltd. · 1 drug in this class
Otsuka Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OPC-12759 — Competitive Intelligence Brief. https://druglandscape.com/ci/opc-12759. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab